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at increased risk of death
Susan E Howlett1,2,3*, Michael RH Rockwood1, Arnold Mitnitski1 and Kenneth Rockwood1,4,5Abstract
Background: Older adults are at an increased risk of death, but not all people of the same age have the same risk.
Many methods identify frail people (that is, those at increased risk) but these often require time-consuming
interactions with health care providers. We evaluated whether standard laboratory tests on their own, or added to a
clinical frailty index (FI), could improve identification of older adults at increased risk of death.
Methods: This is a secondary analysis of a prospective cohort study, where community dwelling and
institutionalized participants in the Canadian Study of Health and Aging who also volunteered for blood collection
(n = 1,013) were followed for up to six years. A standard FI (FI-CSHA) was constructed from data obtained during
the clinical evaluation and a second, novel FI was constructed from laboratory data plus systolic and diastolic blood
pressure measurements (FI-LAB). A combined FI included all items from each index. Predictive validity was tested
using Cox proportional hazards analysis and discriminative ability by the area under receiver operating characteristic
(ROC) curves.
Results: Of 1,013 participants, 51.3% had died by six years. The mean baseline value of the FI-LAB was 0.27
(standard deviation 0.11; range 0.05 to 0.63), the FI-CSHA was 0.25 (0.11; 0.02 to 0.72), and the combined FI was 0.26
(0.09; 0.06 to 0.59). In an age- and sex-adjusted model, with each increment in the FI-LAB, the hazard ratios
increased by 2.8% (95% confidence interval 1.02 to 1.04). The hazard ratios for the FI-CSHA and the combined FI
were 1.02 (1.01 to 1.03) and 1.04 (1.03 to 1.05), respectively. The FI-LAB and FI-CSHA remained independently
associated with death in the face of the other. The areas under the ROC curves were 0.72 for FI-LAB, 0.73 for
FI-CSHA and 0.74 for the combined FI.
Conclusions: An FI based on routine laboratory data can identify older adults at increased risk of death. Additional
evaluation of this approach in clinical settings is warranted.
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Frailty is an important problem for aging societies [1].
Increasingly, there is a sense that societies need to begin
frailty screening and assessment [2], even though lack of
consensus about just how to do this is acknowledged [3].
Frail older adults who become acutely ill are seen as be-
ing at particular risk, especially if exposed to the hazards
of routine hospital care [4-6] without mitigation by spe-
cialized geriatric interventions [7].* Correspondence: susan.howlett@dal.ca
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unless otherwise stated.Reflecting the lack of consensus, various scales to
measure frailty are used [8]. One common approach is
to quantify frailty with a frailty index (FI), based on the
accumulation of health deficits [9-11]. These deficits
can be symptoms, clinical signs, diseases, laboratory
abnormalities or other measures [11]. An FI score is
achieved by counting the number of deficits in an indi-
vidual and dividing by the total number of deficits
measured to produce a score between 0 and 1; a higher
score indicates greater frailty [10,11]. For a deficit to
be included in an FI it must be shown that its preva-
lence increases with age, that it does not become too
prevalent at some younger age and that it is associated
with adverse outcomes [11]. Thus, an FI score providesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical and laboratory data used to construct
the FI-LAB
Variablea Low cut-off High cut-off
Albumin (g/L) 32 45
AST (SGOT; IU/L) 8 33
BP, supine systolic (mmHg) 90 140
BP, supine diastolic (mmHg) 60 90
Calcium (mM) 2.3 2.7
Creatinine (μM) 53 106
Folate (nM) 11 57
Folate, RBC (nM) 376 1450
Glucose, fasting (mM) 3.9 6.1
Hemoglobin (g/L)b 135 180
Mean corpuscular volume (fL) 80 96
Phosphatase, alkaline (IU/L) 20 130
Phosphorus, inorganic (mM) 0.74 1.52
Potassium (mM) 3.8 5
Protein, total (g/L) 60 78
Sodium (mM) 136 142
TSH (μIU/L) 0.5 5
Thyroxine (T4; nM) 71 161
T4, Free (pM) 12 30
Urea (mM) 2.9 8.2
VDRL 0 0
Vitamin B12 (pg/L) 118 701
White blood cells (number/L) 1.8 × 109 7.8 × 109
aNormal reference values for blood work were from Henry [18]. Reference
values for normal blood pressure were from Jones et al. [19] and Pickering
et al. [20]. bNote that normal references values for hemoglobin differed
between the sexes so for women, the low cut-off was 120 g/L and the high
cut-off was 160 g/L. AST, aspartate aminotransferase; BP, blood pressure;
FI-LAB, Laboratory frailty indes; RBC, red blood cells; TSH, thyroid-stimulating
hormone; VDRL, Venereal Disease Research Laboratory.
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izes the risk of adverse outcomes, including death.
In clinical care, the ideal frailty screening tool would
quantify frailty based on data that are collected routinely.
In the hospital setting for example, admission typically is
associated with a large number of blood tests and routine
physical measures (for example, blood pressure) that
require minimal participation by patients. Recent work
on measuring frailty in mice suggests that, in combination,
many such tests show minor abnormalities that, in the ag-
gregate contribute to risk [12]. We wondered whether this
might also obtain with routine physical assessment and
laboratory test data that are often collected clinically.
For this reason, in a re-analysis of data from the clinical
examination conducted during the first wave of the
Canadian Study of Health and Aging (CSHA), our ob-
jectives were: 1) to develop an FI based only on routine
physical and laboratory tests (FI-LAB); 2) to validate
the FI-LAB in relation to age, sex and distribution; and
3) to test its predictive value in relation to death. Here,
we show that an FI based on routine laboratory tests
identifies older adults at an increased risk of death.
Methods
Participants, setting and sample
The CSHA is a cohort study of health problems of older
adults (aged 65+ at baseline). Community-dwelling
participants were screened using a cognitive test (the
Modified Mini-Mental State examination-3MS) [13].
As detailed elsewhere [14], those who screened positive
(n = 1,614) and a comparison group included in a separate
risk factor study (n = 731) were invited to a clinical examin-
ation; 1,659 completed that examination. Institutionalized
participants were not screened but went straight to a
clinical examination (n = 1,255); mortality data were
obtained at the five year follow-up in 1996/1997 [15]. The
clinical examination included a history from participants
and/or knowledgeable informants, as well as hospital re-
cords and routine clinical laboratory data, where available.
Of the 2,914 participants who had a clinical examination,
the present study used a subset from both community-
dwelling (n = 683) and institutionalized (n = 330) partici-
pants, for whom there were sufficient items to construct
an FI relevant to both samples and who in addition
had laboratory data. These 1,013 subjects represented
74% of the 1,375 clinical interview participants who
had laboratory data.
Health measures/deficits
First, a standard FI (FI-CSHA) was constructed from data
obtained during the clinical evaluation as described in detail
in previous studies by our group (for example, [11,16,17]).
The FI was composed of up to 38 variables used in the
initial CSHA clinical examination [see Additional file 1:Table S1]. Each self-reported medical condition, disease
history, symptom, and health rating variable satisfied
the criteria for being a deficit as described previously
[11]. An FI score was calculated where more than 60%
of the variables were available for a given individual.
Although clinical data were available for 1,375 individuals,
362 were excluded from analysis due to missing data to
yield a total sample size of 1,013.
Next, we developed an FI (the FI-LAB) of up to 23
variables based on 21 routine blood tests plus measured
systolic and diastolic blood pressure (Table 1). This lat-
ter, novel FI was called the ‘laboratory FI’ or ‘FI-LAB’.
The FI-LAB was constructed by first coding each variable
as either 0 or 1, where ‘0’ indicates that values are within
the normal cut-offs and ‘1’ indicates that values are either
above or below the normal cut off values illustrated in
Table 1. An FI-LAB score was calculated only if more
than 70% of the lab variables were available for a given
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as the number of deficits present divided by the total
number of deficits measured. For example, an individ-
ual with no deficits would have an FI-LAB score of 0,
whereas one in whom all possible deficits were present
would have the theoretical maximal FI-LAB score of 1. In a
separate analysis, we added the deficit scores in the FI-LAB
and the deficit scores in the FI-CSHA and divided by the
new total to produce a ‘combined’ FI score.
Outcomes
The major outcome was survival (that is, died or survived)
over up to six years of follow-up. Decedent data were
obtained from the Registrar of Vital Statistics in each
province as well as from interviews with spouses or next
of kin of study participants who had died.
Standard protocol approvals, registrations and
patient consents
Data collection was approved by the ethics review process
for the CSHA. Approval for the secondary analyses came
from the Research Ethics Committee of the Capital District
Health Authority, Halifax, Nova Scotia, Canada. All partici-
pants (or designates) signed informed consent forms.
Statistical analysis
Demographic and clinical characteristics were expressed as
either a percentage of the total sample or as the mean ± SD,
or in some cases, as the mean ± SE. Density distribu-
tions for each of the FI-CSHA, FI-LAB and combined
FI scores were plotted and the median, minimal and
maximal values were calculated. The age-specific dis-
tribution of each FI was estimated by plotting the mean
of the natural logarithm of the FI score at each year of
age from age 65 onwards; data were fitted with a linear
regression function, and the fit, slope and intercept
were evaluated. The relationship between the FI-CSHA
and the FI-LAB was investigated by first calculating
the mean of the FI-CSHA in increments of 0.05. Then
the average FI-LAB values were plotted as a function of
the FI-CSHA for each increment and the resulting line
was fitted by linear regression. The distribution of the FI by
months to death was evaluated with Kaplan-Meier survival
analysis. For purposes of presentation, the Kaplan-Meier
survival curves were presented for four grades for each FI
(<0.10, 0.10 to 0.22, 0.23 to 0.45 and >0.45). To investigate
the impact of FIs on mortality, Cox proportional hazard
regression models adjusted for age and sex were used. The
FI values were converted to integers between 0 and 100 by
rounding them after multiplying them by 100, giving equal
percent increments.
Some analyses were performed using codes developed in
Matlab (version 2007, Mathworks Inc.). Additional analyses
were performed either with SPSS (IBM SPSS Statistics,Version 21) or Sigma Plot 11.0 (Systat Software, Inc.,
Point Richmond, CA, USA). Graphs were created with
Sigma Plot 11.0. The statistical significance level was
set at P <0.05.
Results
Of the 1,375 people with both clinical examinations
and laboratory data, complete data were available on
1,013, of whom vital status was known for 986 (97.3%;
Additional file 1: Figure S1). Selected demographic and
clinical characteristics of the study population, subdi-
vided by grades of frailty for both the FI-CSHA and the
FI-LAB, are illustrated in Table 2. The mean frailty
scores increased with age for both frailty measures.
Mean FI-CSHA scores increased from 0.07 ± 0.02 in
the least frail group to 0.50 ± 0.05 in the frailest group
(Table 2). Similar results were seen when the FI-LAB
scores were used to stratify frailty. The average FI-LAB
values increased from 0.08 ± 0.02 in the group with the
lowest scores to 0.50 ± 0.04 in the group with the high-
est frailty (Table 2). Of note, the proportion of women
with low FI scores was much higher when frailty was
stratified by FI-LAB scores compared to the FI-CSHA. The
mean combined FI scores also increased from 0.08 ± 0.01
in the group with the lowest scores to 0.50 ± 0.04 in
the group with the highest frailty scores (Table 2). The
characteristics of the 372 excluded cases (mean (±SD)
FI-CSHA = 0.26 ± 0.12; mean age = 81.9 ± 7.9 years; 64.4%
women) were similar to those of the 1,013 included cases.
To compare the distribution of FI scores for the three
different FI instruments used in this study, frequency
distributions for each were plotted. Figure 1A shows a
frequency distribution of the FI-CSHA scores obtained
for the cohort investigated in this study. The distribution
was slightly skewed to the left, with a mean of 0.25 ± 0.11
(±SD) and a median of 0.24. The minimum FI-CSHA
score observed was 0.02 while the maximum was 0.72
(Figure 1A), consistent with the idea that there is a
sub-maximal limit to frailty near 0.7. The frequency
distribution for the FI-LAB scores is shown in Figure 1B.
This distribution had a mean of 0.27 ± 0.12 (±SD) and a
median of 0.27. The minimal and maximal FI-LAB scores
were 0.05 and 0.63, respectively (Figure 1B). Figure 1C
shows that the frequency distribution for the combined FI
scores was similar to the distribution of the two parent
index scores. This distribution was slightly skewed to the
left with a mean of 0.26 ± 0.09 (±SD), a median of 0.25
and minimal and maximal scores of 0.06 and 0.59, re-
spectively (Figure 1C).
The log of each FI score increased linearly with age
(data not shown). The r2 values were 0.57 for the FI-CSHA,
0.62 for the FI-LAB and 0.69 for the combined FI. Regres-
sion lines fitted through the data had slopes of 0.015, 0.012
and 0.013 for the FI-CSHA, the FI-LAB and the combined
Table 2 Baseline demographic and clinical characteristics and mortality by grades of frailty
Baseline Characteristic Grades of the FI
FI-CSHA <0.10 0.10 to 0.22 0.23 to 0.45 >0.45
Number = 78 Number = 349 Number = 539 Number = 47
Mean age, years (±SD) 76.2 ± 6.1 80.2 ± 7.2 82.1 ± 7.1 83.3 ± 5.6
Mean FI-CSHA (±SD) 0.073 ± 0.019 0.164 ± 0.034 0.309 ± 0.062 0.500 ± 0.051
Women (%) 48.7 59.7 65.1 53.2
Institutionalized (%) 1.3 25.5 45.7 4.3
Mortality (%) 25.6 39.8 60.1 70.2
FI-LAB <0.10 0.10 to 0.22 0.23 to 0.45 >0.45
Number = 56 Number = 255 Number = 645 Number = 57
Mean age, years (±SD) 77.8 ± 6.6 80.1 ± 7.3 81.5 ± 7.1 83.6 ± 6.8
Mean FI-LAB (±SD) 0.083 ± 0.019 0.168 ± 0.027 0.310 ± 0.063 0.503 ± 0.040
Women (%) 60.7 67.8 60.5 47.4
Institutionalized (%) 19.6 30.2 35.0 43.9
Mortality (%) 19.6 44.7 54.4 77.2
Combined FI <0.10 0.10 to 0.22 0.23 to 0.45 >0.45
Number = 15 Number = 346 Number = 635 Number = 17
Mean age, years (±SD) 74.5 ± 4.7 79.0 ± 7.0 82.3 ± 7.0 82.6 ± 6.0
Mean combined FI (±SD) 0.080 ± 0.013 0.173 ± 0.033 0.303 ± 0.055 0.501 ± 0.039
Women (%) 53.3 58.1 64.3 41.2
Institutionalized (%) 0 19.9 42.4 5.9
Mortality (%) 6.7 33.5 61.1 88.2
FI, frailty index; FI-CSHA, standard frailty index; FI-LAB, laboratory frailty index; SD, standard deviation.
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and the FI-LAB scores were linearly related, the FI-CSHA
scores were plotted as a function of the FI-LAB scores
(Figure 2). The average FI-LAB scores increased as the
FI-CSHA increased; this relationship was a very good fit
to a straight line (r2 = 0.81).
Mortality rates generally increased as the frailty scores
rose, although this effect was more marked with the
FI-LAB than with the FI-CSHA scores (Table 2). Mor-
tality also increased significantly as the frailty scores
increased (Table 2, Figure 3). Note that in an age and
sex adjusted model, each contributed independently:
the odds ratio for the FI-LAB =1.03, 95% CI =1.01,
1.04, versus FI-CSHA = 1.04, 95%CI = 1.02, 1.05. The
combined FI showed the clearest separation of groups
by grades of frailty (Figure 3), and was associated with
the highest hazard rates in age and sex adjusted models
(Table 3). The impact on the discriminative ability of
combining both FIs was modest: the area under the re-
ceiver operating characteristic (ROC) curve was 0.71
for the FI-CSHA, 0.72 for the FI-LAB and 0.74 for the
combined FI (Additional file 1: Figure S2). Nonethe-
less, together these data show that all three FI scores
identified older adults at increased risk of death.Discussion
We investigated the properties of an FI made up of
information from widely used laboratory tests. That
FI (the FI-LAB) had properties similar to other FIs,
including the FI-CSHA. The latter consists of up to
38 items from the CSHA clinical examination and cor-
responds to most of the items used in a Comprehensive
Geriatric Assessment, which can be summarized as an
FI [5,6,16,17]. Even so, the people classified as at risk
by each method differed in interesting ways. Although
the distributions of the two FIs were similar, as were
their mean ages, fewer people had the lowest FI scores
in both FIs. For example, only 15 people had a com-
bined FI score less than 0.10, compared with 78 for the
FI-CSHA and 56 for the FI-LAB (Table 2). Of these 15,
only 1 died (Figure 3), the lowest mortality rate of the
three FIs (combined, FI-LAB and FI-CSHA). The analogous
case holds for people with the highest scores in each of the
FI-LAB (n = 57) and FI-CSHA (n = 39). Only 17 individuals
had the highest scores in both and of these 15 died
(Table 2). This 88% five-year mortality was the highest
for any FI category. These large differences in mortality
in relation to the combined FI categories were observed
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Figure 1 Frequency distributions for the FI-CSHA and the
FI-LAB. A) The frequency distribution for the FI-CSHA data was
somewhat skewed to the left, with a median of 0.24 and a long right
tail. The maximum FI-CSHA score was 0.72. B) Histogram showing
the frequency distribution for the FI-LAB data collected in this study.
The distribution had a median FI-LAB value of 0.27 and the maximum
observed FI-LAB score was 0.63. C) The distribution of the combined FI
scores was slightly skewed to the left, with a median value of 0.26 and
a maximum of 0.59. The value of n = 1,013 participants in each group.
FI-CSHA, standard frailty index; FI-LAB, laboratory frailty index.
FI-CSHA










Figure 2 Relationship between the FI-CSHA and the FI-LAB.
FI-LAB values were plotted as a function of the FI-CSHA scores. The
FI-CSHA scores were pooled and the means (±SEM) are shown in
increments of 0.05. The FI-LAB increased as FI-CSHA scores increased
(P <0.001). The data were fit with a linear regression as described in
the methods and were a good fit to a straight line (r2 = 0.81).
FI-CSHA, standard frailty index; FI-LAB, laboratory frailty index; SEM,
standard error of the mean.
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cations could be more finely graded. Even so, we have
resisted finer grades of the combined FI, on the grounds
that, from a clinical point of view, knowing the highest
and the lowest risks is most important: people of inter-
mediate risk represent variations on the usual case, and
typically receive usual management without useful pre-
cision in prognosis. In any case, testing how much infor-
mation comes from the nature of the added items, and
how much comes from their number is best addressed
in a different datatset.
Additional questions remain, however, such as whether
the smaller number of people with the fewest things,
or most things, wrong reflects a specific increase in in-
formation from laboratory data, or whether that might be
shown simply by increasing the number of items consid-
ered in an FI. Here, the distribution of the items in each FI
suggests some comparability (and is reassuring in relation
to combining items), but their independent contribution
in a multivariable model suggests that they are offering
independent information. The latter suggests that sub-
clinical information, or at least information more precisely
detected with laboratory tests, could offer additional
insights. As detailed elsewhere [21,22], frailty that is
macroscopically detectable represents the build-up of
subcellular, tissue and organ deficits, being damage at
those levels that has gone either unremoved or unrepaired.
The lethality of any clinical/macroscopic deficits on a back-
ground of subclinical/microscopic deficits is suggested by
the combined FI hazard rate being the highest, and by
the notably diminished survival of the frailest group
Time (months)






























































Figure 3 Kaplan-Meier survival curves for grades of the FI.
A) Survival over the course of the study plotted as a function of
grades of the FI-CSHA. The least frail group (frailty score <0.10)
showed little mortality over the course of the study whereas the
most frail group (frailty score >0.45) showed very high mortality.
Differences between groups were statistically significant between all
four grades of frailty when analyzed with a log-rank test (P <0.05).
B) Survival curves for grades of frailty assessed by the FI-LAB scores.
There were significant differences in survival between subjects at all
four levels when FI-LAB scores were used to grade frailty (P <0.05;
log rank test). C) Kaplan-Meier survival curves for ‘combined’ FI scores
obtained by merging the FI-CSHA and the FI-LAB scores. Differences in
mortality between the four grades of frailty were most evident when
the combination FI scores were used (P <0.05; log rank test). FI-CSHA,
standard frailty index; FI-LAB, laboratory frailty index.
Howlett et al. BMC Medicine 2014, 12:171 Page 6 of 8
http://www.biomedcentral.com/1741-7015/12/171(FI >0.45) in the combined FI (Figure 3, Panel C, compare
with Panels A and B).
Our data must be interpreted with caution. Our sample,
although population-based, is not representative. Given that
it was drawn from the clinical examination database, it is
older and contains proportionally more institutionalized
people than the population from which it was drawn. Even
within the clinical sample, developing an FI with items that
were relevant for both community-dwelling and institution-
alized people was a challenge: for example, no one in insti-
tutional care is independent in any instrumental activities
of daily living (ADLs), and few community-dwelling people
have fecal incontinence or behavioral problems. In conse-
quence, meeting all criteria for creating an FI-CSHA with
sufficient non-missing data meant that only 1,013 of 1,375
people with laboratory test information could be used. Even
so, relaxing the criterion to allow up to 18 (of 38) variables
to be missing (compared with the usual requirement for
not calculating an FI for anyone for whom more than
20% of the items are missing) added another 158 subjects,
without changing the properties of the resulting FI. Simi-
larly, the mean age of the 362 people for whom we did not
calculate an FI-LAB was 81.9 years (64.4% female) com-
pared to 81.1 years (61.6% female) for those for whom we
did calculate an FI-LAB. Likewise, the mean FI-CSHA
score was 0.26 when all 1,375 subjects were used com-
pared to 0.25 when only the 1,013 people investigated
in this paper were considered. Still, understanding
whether laboratory data will add value in more repre-
sentative samples, or in other clinical samples, requires
cross-validation in other datasets. In other settings,
different or additional laboratory tests might be used
reflecting local differences in relation to congenital
and acquired disease, or those associated with lifestyle
or environment (for example, thalassemia, histoplas-
mosis, alcoholism, air pollution). More recent reports
might also change which tests were selected, for ex-
ample, substituting alanine transaminase for aspartate
transaminase [23-25].
Here, we tested the predictive validity of the frailty
measures in relation to mortality. With each version of
the FI, higher FI scores were associated with greater
mortality, verified in a multivariable model that in-
cluded age. Although death has the advantage of being
a dichotomous, unambiguous and relevant example of
an adverse outcome, not everyone dies a frail death. In
consequence, it is important to distinguish between
the exercise of predicting mortality per se and using it
to validate the notion that more deficits are associated
with greater risk. For example, were mortality prediction to
be all that motivated our inquiry, then the FI would include
chronological age, as evidenced by its persisting significance
in each of the Cox proportional hazards models (Table 3).
In the present context, this would, of course, be perverse:








Sex −0.404 0.102 −3.989 0.67 0.54 to 0.82
Age 0.069 0.008 9.207 1.07 1.06 to 1.09
FI-CSHA 0.021 0.004 4.865 1.02 1.01 to 1.03
Sex −0.306 0.102 −3.002 0.74 0.60 to 0.90
Age 0.066 0.008 8.753 1.07 1.05 to 1.08
FI -LAB 0.028 0.005 5.991 1.03 1.02 to 1.04
Sex −0.355 0.101 −3.505 0.70 0.57 to 0.86
Age 0.064 0.008 8.442 1.07 1.05 to 1.08
Combined FI 0.040 0.006 7.058 1.04 1.03 to 1.05
FI, frailty index; FI-CSHA, standard frailty index; FI-LAB, laboratory frailty index.
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age is highly associated with the risk of adverse health out-
comes (including death), not everyone of the same age has
the same risk. The suggestion of the FI – that people with
the most things wrong are at the highest risk – also has the
advantage of being parsimonious, and of being sensible on
its face, which itself is another form of validation [26].
The addition of laboratory test data also is of interest
in understanding the associations between specific test
abnormalities and frailty, as is commonly undertaken in
inquiries about putative frailty mechanisms. For example,
some groups have evaluated individual or even small num-
bers of laboratory tests [27-30]. A burgeoning literature on
biomarkers, typically motivated by discrete mechanis-
tic hypotheses, often considers such tests individually
[31-34]. Our data suggest that any such results need to
be interpreted in the context of the overall health state
of the organism, if a general claim about frailty is to be
made. Consider that the mean value of the FI score is
typically closely related to age – or, as has been argued
elsewhere – is a measure of biological age [10,35,36].
Aging is associated with a very large number of cellular
and tissue mechanisms [37]. Finding associations with
any single test abnormality can be helpful, but under-
standing where this fits in relation to other test abnormal-
ities is an important step in aiming to gain a mechanistic
understanding and in understanding systems effects. Our
data suggest that, particularly for those sorts of inquiries,
looking at the contribution of any single health deficit in
isolation will be pragmatically difficult and theoretically
dubious. A similar argument obtains in relation to under-
standing age-related mechanisms. Support for the latter
comes from a recent study which shows that later life
changes in myocyte structure and function are more
closely tied to an FI than to chronological age [12]. As
argued elsewhere, extending work on frailty to animal
models can allow for exploration of mechanisms of
both frailty and, more broadly, aging itself [38]. Finally,the observation here that more women had lower FI
scores using the FI-LAB than using the FI-CSHA is of
interest. Of note, either way women had lower mortality
than did men for any level of either FI. The more conser-
vative estimate of frailty status observed with the FI-LAB
might be an explanation for the so-called male–female
mortality-morbidity paradox [39]. This intriguing observa-
tion needs to be pursued further.
Conclusions
The results of this study demonstrate that an FI con-
structed from routinely collected laboratory and clinical
data identifies older adults at increased risk of death. A
large number of additional inquiries are suggested by
these current findings. Beyond replication, and as a
probe for understanding mechanisms, the feasibility and
utility of adding a large number of items to an FI using
commonly evaluated laboratory tests might importantly
advance routine frailty assessment, especially when these
test results are used in conjunction with other relevant
items from electronic medical records. These consider-
ations are motivating additional inquiries by our group. In
particular, further evaluation in clinical settings of adding
routinely collected laboratory data to an FI is warranted.
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